Linden has been responsible for managing the biotechnology strategies at Framlington Equities, since 2011. She is also the global biotechnology specialist in the internal research organisation. Prior to AXA IM, she worked at Clear River Capital where she was responsible for pharmaceutical and biotechnology research. She started her career in 2003 at Goldman Sachs.